John Libbey Eurotext




Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn’s disease
European Journal of Dermatology. Volume 13, Number 3, 258-60, May 2003, Therapy
Free Article
Author(s) : Alessandro ZACCAGNA, Alberto BERTONE, Paolo PUIATTI, Franco PICCIOTTO, Tatiana SPRUJEVNIK, Renato SANTUCCI, Francesco Paolo ROSSINI
Summary : Here we report a case of Pyoderma gangrenosum (PG) associated with Crohn’s disease successfully treated with infliximab. The efficacy of this drug in many inflammatory diseases has already been reported, but its use in PG has only been seen in very few cases. Our study confirms that this therapy is a valid alternative solution for treating PG, which is often unresponsive to conventional therapies.
Keywords : Crohn’s disease, infliximab, neutrophilic dermatoses, Pyoderma gangrenosum, therapy, tumor-necrosis-factor-alpha

Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn’s disease